SLC began as an API company but has since become a vertically integrated supplier of finished dosage formulations.
History
Vertical Integration Stage
- 2022- The Company and Shenzhen China Resources GOSUN Pharmaceuticals signed an exclusive sales contract for Ertapenem in the mainland market
- 2022- The company disposal of the plant and its ancillary equipment in Chunan Ⅱ Science Park
- 2021- SLC BioPharm Co., Ltd. subsidiary company established
- 2020- Our Chinese company name has changed to 「松瑞製藥股份有限公司」as of 24th June, where the English company name remains unchanged as Savior Lifetec Corporation (SLC).
- 2019- US ANDA Approval for Ertapenem
- 2018- UK ANDA Approval for Ertapenem
- 2016- US ANDA Approval for Meropenem
- 2015- Savior Lifetec Corporation (4167.TWO) is officially listed on TPEx
- 2014- Injection Plant(IP)in Tainan, Taiwan Passes US FDA cGMP Audit
- 2013- Injectable facility passes Spain AEMPS inspection
- 2013- Injectable facility passes Taiwan TFDA inspection
- 2012- Savior Lifetec Corporation (4167.TWO) registered on the Emerging Board
- 2011- Injectable plant at Tainan Science Park established
Founding Stage
- 2011- API facility passes US FDA inspection
- 2010- API facility passes UK MHRA inspection
- 2009- API facility passes Japan PMDA inspection
- 2007- First to register US DMF for Meropenem
- 2006- Branch site at Tainan Science Park established
- 2006- API facility passes Taiwan Ministry of Health inspection
- 2006- First to register US DMF for Imipenem-Cilastatin
- 2004- HQ site at Chunan Science Park established